Back to Screener

Healthcare

PharmaCom BioVet, Inc.(PHMB)

Live Price

Offline

$0.0001

+0.00% today

1Y Change

+0.00%

Window

Jun 23, 2025 โ†’ Jun 8, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
0.0%
Dividend Yield
0.0%

Coverage: 241 bars ยท Jun 23, 2025 โ†’ Jun 8, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

PharmaCom BioVet, Inc. (PHMB) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines PHMB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PHMB

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PHMB Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PHMB and SPY.

Calendar-year return history is still loading or unavailable.
PharmaCom BioVet, Inc. logo

Company Overview

PharmaCom BioVet, Inc.

Other OTC

PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer. The company was formerly known as ABV Gold Inc. and changed its name to PharmaCom BioVet, Inc. in August 2008. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina.

Leadership
Ira Frohman
IPO Date
May 5, 1999
Street Address
6040-A Six Forks Road
Mailing
Raleigh, NC, 27609
Region
Raleigh, NC, US
Reporting Currency
USD
Investor Line
919 604 4887
Last Updated
May 3, 2026
ISIN: US71720A1079
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
0.0%
Free Cash Flow
0.0%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
0.0%
ROIC
0.0%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
โ€”

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.